{"title":"Guidelines for the treatment of malaria","nid":226,"vid":2006,"created":1567056872,"changed":1574833413,"field_accordian_header":[{"field_accordian":[{"field_title":"Rapid diagnostic test (RDT)","field_content":"<p>All cases of suspected malaria should have a parasitological test (microscopy or Rapid diagnostic test (RDT)) to confirm the diagnosis.<\/p>\r\n\r\n<p>Both microscopy and RDTs should be supported by a quality assurance programme.<\/p>\r\n\r\n<p><em>Good practice statement<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"Diagnosis of malaria"},{"field_accordian":[{"field_title":"Treatment of uncomplicated <i>P. falciparum<\/i> malaria","field_content":"<p>Treat children and adults with uncomplicated <em>P. falciparum<\/em> malaria (except pregnant women in their first trimester) with one of the following recommended artemisinin-based combination therapies (ACT):<\/p>\r\n\r\n<ul>\r\n\t<li>artemether + lumefantrine<\/li>\r\n\t<li>artesunate + amodiaquine<\/li>\r\n\t<li>artesunate + mefloquine<\/li>\r\n\t<li>dihydroartemisinin + piperaquine<\/li>\r\n\t<li>artesunate + sulfadoxine\u2013pyrimethamine (SP)<\/li>\r\n<\/ul>\r\n\r\n<p><em>Strong recommendation, high-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Duration of ACT treatment","field_content":"<p>ACT regimens should provide 3 days\u2019 treatment with an artemisinin derivative.<\/p>\r\n\r\n<p><em>Strong recommendation, high-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Revised dose recommendation for dihydroartemisinin + piperaquine in young children","field_content":"<p>Children &lt; 25kg treated with dihydroartemisinin + piperaquine should receive a minimum of 2.5 mg\/kg body weight (bw) per day of dihydroartemisinin and 20 mg\/kg bw per day of piperaquine daily for 3 days.<\/p>\r\n\r\n<p><em>Strong recommendation based on pharmacokinetic modelling<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Reducing the transmissibility of treated <i>P. falciparum<\/i> infections","field_content":"<p>In low-transmission areas, give a single dose of 0.25 mg\/kg bw primaquine with ACT to patients with <em>P. falciparum<\/em> malaria (except pregnant women, infants aged &lt; 6 months and women breastfeeding infants aged &lt; 6 months) to reduce transmission. Testing for glucose-6-phosphate dehydrogenase (G6PD) deficiency is not required.<\/p>\r\n\r\n<p><em>Strong recommendation, low-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"Treating uncomplicated <i>P. falciparum<\/i> malaria"},{"field_accordian":[{"field_title":"First trimester of pregnancy","field_content":"<p>Treat pregnant women with uncomplicated <em>P. falciparum<\/em> malaria during the first trimester with 7 days of quinine + clindamycin.<\/p>\r\n\r\n<p><em>Strong recommendation<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Infants less than 5kg body weight","field_content":"<p>Treat infants weighing &lt; 5 kg with uncomplicated <em>P. falciparum<\/em> malaria with ACT at the same mg\/kg bw target dose as for children weighing 5 kg.<\/p>\r\n\r\n<p><em>Strong recommendation<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Patients co-infected with HIV","field_content":"<p>In people who have HIV\/AIDS and uncomplicated <em>P. falciparum<\/em> malaria, avoid artesunate + SP if they are being treated with co-trimoxazole, and avoid artesunate + amodiaquine if they are being treated with efavirenz or zidovudine.<\/p>\r\n\r\n<p><em>Good practice statement<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Non-immune travellers","field_content":"<p>Treat travellers with uncomplicated <em>P. falciparum<\/em> malaria returning to non-endemic settings with ACT.<\/p>\r\n\r\n<p><em>Strong recommendation, high-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Hyperparasitaemia","field_content":"<p>People with <em>P. falciparum<\/em> hyperparasitaemia are at increased risk for treatment failure, severe malaria and death and should be closely monitored, in addition to receiving ACT.<\/p>\r\n\r\n<p><em>Good practice statement<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"Treating uncomplicated <i>P. falciparum<\/i> malaria in special risk groups"},{"field_accordian":[{"field_title":"Blood stage infection","field_content":"<p>If the malaria species is not known with certainty, treat as for uncomplicated P. <em>falciparum<\/em> malaria.<\/p>\r\n\r\n<p><em>Good practice statement <\/em><\/p>\r\n\r\n<p>In areas with chloroquine-susceptible infections, treat adults and children with uncomplicated P. <em>vivax<\/em>, P. <em>ovale<\/em>, P. <em>malariae<\/em> or P. <em>knowlesi<\/em> malaria with either ACT (except pregnant women in their first trimester) or chloroquine.<\/p>\r\n\r\n<p><em>Strong recommendation, high-quality evidence<\/em><\/p>\r\n\r\n<p>In areas with chloroquine-resistant infections, treat adults and children with uncomplicated P. <em>vivax<\/em>, P. <em>ovale<\/em>, P. malariae or P. knowlesi malaria (except pregnant women in their first trimester) with ACT.<\/p>\r\n\r\n<p><em>Strong recommendation, high-quality evidence <\/em><\/p>\r\n\r\n<p>Treat pregnant women in their first trimester who have chloroquine-resistant P. <em>vivax<\/em> malaria with quinine.<\/p>\r\n\r\n<p><em>Strong recommendation, very low-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"Treating uncomplicated <i>P. vivax, P. ovale, P. malariae or P. knowlesi<\/i> malaria"},{"field_accordian":[{"field_title":"Pregnant and breastfeeding women","field_content":"<p>The G6PD status of patients should be used to guide administration of primaquine for preventing relapse.<\/p>\r\n\r\n<p><em>Good practice statement <\/em><\/p>\r\n\r\n<p>To prevent relapse, treat P. vivax or P. ovale malaria in children and adults (except pregnant women, infants aged &lt; 6 months, women breastfeeding infants aged &lt; 6 months, women breastfeeding older infants unless they are known not to be G6PD deficient, and people with G6PD deficiency) with a 14-day course (0.25-0.5 mg\/kg bw daily) of primaquine in all transmission settings.<\/p>\r\n\r\n<p><em>Strong recommendation, high-quality evidence<\/em><\/p>\r\n\r\n<p>In people with G6PD deficiency, consider preventing relapse by giving primaquine base at 0.75 mg\/kg bw once a week for 8 weeks, with close medical supervision for potential primaquine-induced haemolysis.<\/p>\r\n\r\n<p><em>Conditional recommendation, very low-quality evidence <\/em><\/p>\r\n\r\n<p>When G6PD status is unknown and G6PD testing is not available, a decision to prescribe primaquine must be based on an assessment of the risks and benefits of adding primaquine.<\/p>\r\n\r\n<p><em>Good practice statement<\/em><\/p>\r\n\r\n<p><strong>Pregnant and breastfeeding women<\/strong><\/p>\r\n\r\n<p><br \/>\r\nIn women who are pregnant or breastfeeding, consider weekly chemoprophylaxis with chloroquine until delivery and breastfeeding are completed, then, on the basis of G6PD status, treat with primaquine to prevent future relapse.<\/p>\r\n\r\n<p><em>Conditional recommendation, moderate-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"Preventing relapse in <i>P. vivax<\/i> or <i>P. ovale<\/i> malaria"},{"field_accordian":[{"field_title":"Revised dose recommendation for parenteral artesunate in young children","field_content":"<p>Treat adults and children with severe malaria (including infants, pregnant women in all trimesters and lactating women) with intravenous or intramuscular artesunate for at least 24 h and until they can tolerate oral medication. Once a patient has received at least 24 h of parenteral therapy and can tolerate oral therapy, complete treatment with 3 days of ACT (add single dose primaquine in areas of low transmission).<\/p>\r\n\r\n<p><em>Strong recommendation, high-quality evidence<\/em><\/p>\r\n\r\n<p><em><strong>Revised dose recommendation for parenteral artesunate in young children <\/strong><\/em><\/p>\r\n\r\n<p>Children weighing &lt; 20 kg should receive a higher dose of artesunate (3 mg\/kg bw per dose) than larger children and adults (2.4 mg\/kg bw per dose) to ensure equivalent exposure to the drug.<\/p>\r\n\r\n<p><em>Strong recommendation based on pharmacokinetic modelling<\/em><\/p>\r\n\r\n<p><strong><em>Parenteral alternatives where artesunate is not available<\/em><\/strong><\/p>\r\n\r\n<p>If artesunate is not available, use artemether in preference to quinine for treating children and adults with severe malaria.<\/p>\r\n\r\n<p><em>Conditional recommendation, low-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"Treating severe malaria"},{"field_accordian":[{"field_title":"Pre-referral treatment options","field_content":"<p>Where complete treatment of severe malaria is not possible but injections are available, give adults and children a single intramuscular dose of artesunate, and refer to an appropriate facility for further care. Where intramuscular artesunate is not available use intramuscular artemether or, if that is not available, use intramuscular quinine.<\/p>\r\n\r\n<p><em>Strong recommendation, moderate-quality evidence<\/em><\/p>\r\n\r\n<p>Where intramuscular injection of artesunate is not available, treat children &lt; 6 years with a single rectal dose (10mg\/kg bw) of artesunate, and refer immediately to an appropriate facility for further care. Do not use rectal artesunate in older children and adults.<\/p>\r\n\r\n<p><em>Strong recommendation, moderate-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"Treating cases of suspected severe malaria pending transfer to a higher- level facility (pre-referral treatment)"},{"field_accordian":[{"field_title":"Intermittent preventive treatment in pregnancy","field_content":"<p>In malaria-endemic areas in Africa, provide intermittent preventive treatment with SP to all women in their first or second pregnancy (SP-IPTp) as part of antenatal care. Dosing should start in the second trimester and doses should be given at least 1 month apart, with the objective of ensuring that at least three doses are received.<\/p>\r\n\r\n<p><em>Strong recommendation, high-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Intermittent preventive treatment in infants","field_content":"<p>In areas of moderate-to-high malaria transmission of Africa, where SP is still effective, provide intermittent preventive treatment with SP to infants (&lt; 12 months of age) (SP-IPTi) at the time of the second and third rounds of vaccination against diphtheria, tetanus and pertussis (DTP) and vaccination against measles.<\/p>\r\n\r\n<p><em>Strong recommendation<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Seasonal malaria chemoprevention","field_content":"<p>In areas with highly seasonal malaria transmission in the sub-Sahel region of Africa, provide seasonal malaria chemoprevention (SMC) with monthly amodiaquine + SP for all children aged &lt; 6 years during each transmission season.<\/p>\r\n\r\n<p><em>Strong recommendation, high-quality evidence<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Antimalarial drug quality","field_content":"<p>National drug and regulatory authorities should ensure that the antimalarial medicines provided in both the public and the private sectors are of acceptable quality, through regulation, inspection and law enforcement.<\/p>\r\n\r\n<p><em>Good practice statement<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"Monitoring the efficacy of antimalarial drugs","field_content":"<p>All malaria programmes should regularly monitor the therapeutic efficacy of antimalarial drugs using the standard WHO protocols.<\/p>\r\n\r\n<p><em>Good practice statement<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null},{"field_title":"National adaptation and implementation","field_content":"<p>The choice of ACTs in a country or region should be based on optimal efficacy, safety and adherence.<\/p>\r\n\r\n<p><em>Good practice statement<\/em><\/p>\r\n\r\n<p>Drugs used in IPTp, SMC and IPTi should not be used as a component of first- line treatments in the same country or region.<\/p>\r\n\r\n<p><em>Good practice statement <\/em><\/p>\r\n\r\n<p>When possible, use:<\/p>\r\n\r\n<ul>\r\n\t<li>fixed-dose combinations rather than co-blistered or loose, single-agent formulations; and<\/li>\r\n\t<li>for young children and infants, paediatric formulations, with a preference for solid formulations (e.g. dispersible tablets) rather than liquid formulations.<\/li>\r\n<\/ul>\r\n\r\n<p><em>Good practice statement<\/em><\/p>\r\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"Chemoprevention for special risk groups"}],"field_content_type":{"tid":9,"name":"Accord","class":"accord"},"field_references":null}